You have reached the cached page for https://endpts.com/the-endpoints-slack-interview-siddhartha-mukherjee-on-the-doctor-writer-worldview-ai-and-the-future-of-cancer/

Below is a snapshot of the Web page as it appeared on 30/05/2024 (the last time our crawler visited it). This is the version of the page that was used for ranking your search results. The page may have changed since we last cached it. To see what might have changed (without the highlights), go to the current page.

Bing is not responsible for the content of this page.

The Endpoints Slack interview: Siddhartha Mukherjee on the doctor-writer worldview, AI, and the future of cancer – Endpoints News

May 14, 2024 09:00 AM EDTUpdated May 22, 08:24 AM

R&D

In Focus

The Endpoints Slack interview: Siddhartha Mukherjee on the doctor-writer worldview, AI, and the future of cancer

Andrew Dunn

Senior Biopharma Correspondent

Siddhartha Mukherjee is something of a biotech Renaissance man.

First and foremost, he sees himself as an oncologist. But that core interest has led him …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

The Endpoints Slack interview: Siddhartha Mukherjee on the doctor-writer worldview, AI, and the future of cancer

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Immunovant postpones trial readouts for its late-stage FcRn drug as it prioritizes another

BridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial

Flush with cash, Novo Nordisk Foundation now plans to reinvest some GLP-1 profits into regenerative medicines

Novartis ends development of KRAS drug, citing 'increasing options available'

The biopharma news we’re paying attention to at ASCO

A novel study insight analytics (SIA) methodology improves PANSS data quality and signal detection in a global ...

The End­points Slack in­ter­view: Sid­dhartha Mukher­jee on the doc­tor-writer world­view, AI, and the fu­ture of can­cer

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Im­muno­vant post­pones tri­al read­outs for its late-stage FcRn drug as it pri­or­i­tizes an­oth­er

Bridge­Bio touts ad­di­tion­al AT­TR-CM drug da­ta in new analy­ses of Phase 3 tri­al

Flush with cash, No­vo Nordisk Foun­da­tion now plans to rein­vest some GLP-1 prof­its in­to re­gen­er­a­tive med­i­cines

No­var­tis ends de­vel­op­ment of KRAS drug, cit­ing 'in­creas­ing op­tions avail­able'

The bio­phar­ma news we’re pay­ing at­ten­tion to at AS­CO

A nov­el study in­sight an­a­lyt­ics (SIA) method­ol­o­gy im­proves PANSS da­ta qual­i­ty and sig­nal de­tec­tion in a glob­al ...

The Endpoints Slack interview: Siddhartha Mukherjee on the doctor-writer worldview, AI, and the future of cancer

Immunovant postpones trial readouts for its late-stage FcRn drug as it prioritizes another

BridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial

Flush with cash, Novo Nordisk Foundation now plans to reinvest some GLP-1 profits into regenerative medicines

Novartis ends development of KRAS drug, citing 'increasing options available'

The biopharma news we’re paying attention to at ASCO

A novel study insight analytics (SIA) methodology improves PANSS data quality and signal detection in a global ...